Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07016841

Effects of pHA Hemoperfusion Plus Hemodialysis on Protein-Bound Uremic Toxins

Effects of Conventional Hemodialysis Combined With pHA Hemoperfusion Therapy on Protein-Bound Uremic Toxins in Maintenance Hemodialysis Patients: A Single-Center, Prospective Cohort Study

Status
Recruiting
Phase
Study type
Observational
Enrollment
120 (estimated)
Sponsor
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This single-center, prospective cohort Study evaluates whether adding the pHA130 hemoperfusion cartridge to conventional hemodialysis (HD) or hemodiafiltration (HDF) more effectively reduces protein-bound uremic toxins-specifically indoxyl sulfate (IS) and p-cresyl sulfate (PCS)-in maintenance HD patients. Adults on thrice-weekly, 4-hour HD for at least three months are randomized to one of three arms: HD/HDF alone; HD/HDF plus biweekly pHA130 hemoperfusion; or HD/HDF plus biweekly HA130 hemoperfusion. After a four-week washout, toxin levels are measured at baseline and again at Weeks 4, 12, and 24, with the primary endpoint being the reduction in IS and PCS at Week 24. Secondary endpoints include single-session toxin removal, middle-molecule clearance (β₂-microglobulin, PTH), patient-reported outcomes (itching, sleep, quality of life), and rates of hospitalization and mortality. Safety is closely monitored through adverse event reporting and consistent anticoagulation dosing. Findings will clarify the clinical value of pHA130 hemoperfusion for improving toxin clearance and guiding optimal dialysis strategies.

Conditions

Interventions

TypeNameDescription
DEVICEpHA130 hemoperfusion deviceHP once every 2 weeks.
DEVICEHD/HDFHD twice weekly, HDF once weekly, with each session lasting 4 hours.
DEVICEHA130 hemoperfusion deviceHP once every 2 weeks.

Timeline

Start date
2025-05-12
Primary completion
2026-06-30
Completion
2026-06-30
First posted
2025-06-12
Last updated
2025-06-12

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT07016841. Inclusion in this directory is not an endorsement.